Cedars-Sinai Medical Center has achieved significantly improved survival outcomes for patients undergoing allogeneic stem cell transplants for blood cancers, according to recent rankings from the Center for International Bone and Marrow Transplant Research (CIBMTR). This marks the sixth consecutive year that Cedars-Sinai has excelled in these outcomes, positioning it among the top seven adult transplant centers in the U.S. out of 176 evaluated.
Key factors contributing to this success include a tailored approach to pretransplant conditioning, meticulous graft-versus-host disease (GVHD) prevention, and the strategic selection of younger half-matched donors, often relatives, which facilitates quicker transplants. The institution’s commitment to patient care extends beyond the procedure, with a robust support system designed to monitor patients closely during the critical first 100 days post-transplant, thus mitigating complications.
Cedars-Sinai is also pioneering research into expanding transplant eligibility to patients over 75 years old, previously deemed “too old” for the procedure. This research aims to enhance both survival rates and quality of life in this demographic, reflecting a shift in the understanding of patient capability and outcomes.
The findings highlight the potential for optimizing care pathways in hematopoietic stem cell transplantation and underscore the importance of donor matching and patient-centered care practices in improving graft outcomes and overall survival in patients with blood cancers.
Source: www.cedars-sinai.org
